Financial Press Releases

Award of Share Options and Restricted Stock Units

OXFORD, United Kingdom and CAMBRIDGE, Mass., April 23, 2018 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), announces that the following options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) were granted on 20 April 2018 to the Chief Executive Officer, PDMRs and employees in line with the Company’s Long Term Incentive Plan. The Company has also made a grant of restricted stock units (‘RSUs’) to the Non-Executive Directors under the Company’s 2017 Remuneration...

Published on .

Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report

BERKELEY, Calif., April 23, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention (CDC) published the Advisory Committee of Immunization Practices’ (ACIP) Recommendations for the use of HEPLISAV-B® [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for adults in the US in the Morbidity and Mortality Weekly Report (MMWR) dated April 19. The publication can be found on the CDC’s website here.“Publication in the MMWR represents...

Published on .

Nightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting

LEXINGTON, Mass. and LONDON, April 23, 2018 -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that one oral presentation and four posters have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting taking place April 29 to May 3, 2018, in Honolulu, HI. The presentations include clinical and nonclinical data on Nightstar’s lead...

Published on .

UTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem® to Treat Trauma Patients

CLEVELAND, April 23, 2018 -- The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (NASDAQ:ATHX) today announced plans to conduct a Phase 2 clinical trial evaluating Athersys’ MultiStem® cell therapy for early treatment and prevention of complications after severe traumatic injury. This first-ever study of a cell therapy for treatment of a wide range of traumatic injuries will be conducted at Memorial Hermann-Texas Medical Center, one of the busiest Level 1 trauma...

Published on .

Porton Pharma SolutionsとCodexisがグローバルな提携を発表

米カリフォルニア州レッドウッドシティ & 中国・重慶--(BUSINESS WIRE)--(ビジネスワイヤ)-- Codexis, Inc.(NASDAQ: CDXS)とPorton Pharma Solutions, Ltd.(SZSE: 300363)は、戦略的提携契約を結び、Codexisの世界屈指の生体触媒技術をPortonの世界的なカスタムメイド中間体・医薬品有効成分(API)開発製造事業の中で展開すると発表しました。この提携関係は、増え続ける世界の低分子医薬品に生体触媒の利点を活用することで、新しい低コストで持続可能な製造プロセスの創出を加速します。 提携契約の条件に従い、Codexisは専有の生体触媒ライブラリー、高スループットのスクリーニングおよび酵素製造ノウハウを含め、自社の生体触媒技術の中核的要素をPortonにライセンス提供します。またCodexisは、生体触媒を使用した新しいプロセス・ソリューション創出のためのタンパク質エンジニアリング・プラットフォームCodeEvolver®への優先的アクセスも提供します。Portonは、同社が世界の製薬業界顧客に提供する医薬品開発製造受託(CDMO)サービスに生体触媒技術を採用し、応用方法の最適化を促進するための新しい事業に着手します。さらにPortonは、Codexisのタンパク質エンジニアリング・プラットフォーム技術CodeEvolver®を使用するに当たっての資金面での約束もしています。 この提携関係は、世界の低分子医薬品製造企業に対し、生物触媒がもたらし得るコスト削減、持続可能性の強化、品質改善の利点を再確認するものです。世界的に見てこのような利点の影響を受けている医薬品製造プロセスの数は増え続けており、Codexisは、商業規模の医薬品製造のイノベーションにおける同社生体触媒の寄与に関して、米環境省(EPA)の「グリーンケミストリー・チャレンジ大統領賞」(Presidential...

Published on .

Porton Pharma Solutions and Codexis Launch Global Partnership

REDWOOD CITY, Calif. & CHONGQING, China--(BUSINESS WIRE)--Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits...

Published on .

重庆博腾制药科技股份有限公司与Codexis开启全球伙伴关系

加州雷德伍德城和中国重庆--(BUSINESS WIRE)--(美国商业资讯) -- Codexis, Inc. (NASDAQ: CDXS)与重庆博腾制药科技股份有限公司(Porton Pharma Solutions, Ltd.,深圳证券交易所股票代码:300363)宣布一项战略合作,在博腾的全球定制中间体和活性药物组分(API)开发和制造业务中部署Codexis世界领先的生物催化剂技术。该伙伴关系将加快新的、低成本、可持续的制造工艺的研制和商业化,在越来越多的全球小分子药品中发挥生物催化剂的效益。 按照合作条款,Codexis将其生物催化剂技术的核心要素授权给博腾,包括其专利生物催化剂库、高通量筛选和酶制造技术诀窍。Codexis还将提供其CodeEvolver®蛋白质工程平台技术的优先访问权限,这项技术用于研制新的生物催化剂工艺解决方案。博腾将部署新的运营设施,来推动上述生物催化剂技术在其面向全球制药客户的定制合同开发和制造(CDMO)服务中的采用和最优应用。此外,博腾对利用Codexis的CodeEvolver®蛋白质工程平台技术做出了财务承诺。 该伙伴关系加强了生物催化剂能够给全球小分子药品制造带来的效益,即成本降低、可持续性提升以及产品品质的提高。这些效益已经在影响越来越多的全球药品制造工艺,帮助Codexis凭借其生物催化剂对这些商用级药品制造创新的贡献而赢得美国环保局的三项总统绿色化学挑战奖。 博腾董事长兼首席执行官居年丰(Oliver...

Published on .

重慶博騰製藥科技股份有限公司與Codexis開啟全球夥伴關係

加州紅木城和中國重慶--(BUSINESS WIRE)--(美國商業資訊) -- Codexis, Inc. (NASDAQ: CDXS)與重慶博騰製藥科技股份有限公司(Porton Pharma Solutions, Ltd.,深圳證券交易所股票代碼:300363)宣布一項策略合作,在博騰的全球訂制中間體和活性藥物成分(API)開發和製造業務中部署Codexis世界領先的生物催化劑技術。該夥伴關係將加快新的、低成本、永續的製程建立和商品化,在越來越多的全球小分子藥品中發揮生物催化劑的效益。 按照合作條款,Codexis將其生物催化劑技術的核心要素授權給博騰,包括其專利生物催化劑庫、高通量篩選和酶製造技術訣竅。Codexis還將提供其CodeEvolver®蛋白質工程平臺技術的優先使用權限,這項技術用於建立新的生物催化劑製程解決方案。博騰將部署新的營運設施,來推動上述生物催化劑技術在其全球製藥客戶的委託研究開發暨生產(CDMO)服務中的採用和最佳應用。此外,博騰對利用Codexis的CodeEvolver®蛋白質工程平臺技術做出了財務承諾。 該夥伴關係加強了生物催化劑能夠為全球小分子藥品製造帶來的效益,即成本降低、可持續性提升以及產品品質的提高。這些效益已經在影響越來越多的全球藥品製造過程,幫助Codexis憑藉其生物催化劑對這些商用級藥品製造創新的貢獻而贏得美國環保局的三項總統綠能化學挑戰學術獎(Presidential...

Published on .

Invitation to Kungsleden’s presentation of the first quarter 2018 on April 26 at 8:45 am (CET)

Mon, Apr 23, 2018 12:00 CET On April 26, 2018 at 07.00 am (CET) Kungsleden AB (publ) will publish its first interim report for 2018. Accordingly, Kungsleden invites investors, asset managers, financial analysts and the press to a presentation where CEO Biljana Pehrsson and Deputy CEO and CFO Anders Kvist will present and comment on the first quarter. The report will be published at 07:00 am and is available to download at www.kungsleden.se/financialreports. Follow the presentation via telephone conference...

Published on .

Glaston’s Interim Report 1 January – 31 March 2018: Orders received grew 23%, comparable operating profit at previous year’s level

Mon, Apr 23, 2018 12:00 CET GLASTON CORPORATION                   INTERIM REPORT    23.4.2018  AT 13.00 This release is a summary of Glaston Corporation's Interim Report for January-March 2018. The complete report is attached to this release as a pdf-file. The release is also available on the company's website at the address www.glaston.net.On 26 March 2018, Glaston published...

Published on .

Pricer; New recruitment and organizational change

Mon, Apr 23, 2018 12:00 CET Pricer recruits Edvin Ruud as Vice President Sales effective immediately. In his role, Edvin will align the global sales organization in order to maximize the company’s growth potential. Edvin, who has studied both engineering and business administration, has extensive experience of leading positions in technology-intensive companies such as Ericsson, Cisco and Ciena. Most recently, Edvin came from the role of CEO for Apis Technical Training AB. Edvin reports to Pricer’s...

Published on .

Ahlstrom-Munksjö plans to invest about EUR 9 million for improved financial performance

Mon, Apr 23, 2018 12:00 CET AHLSTROM-MUNKSJÖ OYJ PRESS RELEASE, April 23, 2018 at 12:00 CEST Ahlstrom-Munksjö has decided on two investment projects, totaling EUR 9 million, both with attractive financial returns. This supports Ahlstrom-Munksjö’s strategic ambition to maintain a leading position in selected niches of the global fiber-based solutions market that offer positive growth outlook and are supported by sustainable market drivers. These projects will not materially impact current year’s...

Published on .

Quotidian Technical Highlights on Selected Wireless Communications Stocks -- America Movil, China Mobile, Mobile TeleSystems, and SK Telecom

NEW YORK, April 23, 2018 -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on AMX, CHL, MBT, and SKM which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on America Movil S.A.B. de C.V. (NYSE: AMX), China Mobile Ltd (NYSE: CHL), Public Joint-Stock Company Mobile TeleSystems (NYSE: MBT), and SK Telecom Co. Ltd (NYSE: SKM). Companies...

Published on .